Jim Broderick reels in a $100M Series B to explore a 'new and big' angle of immune regulation
When Jim Broderick launched Massachusetts-based Palleon Pharmaceuticals in 2015, he had an office in Cambridge’s Kendall Square, a bit of seed money, and a blank canvas.
He set out to innovate within a new space in immunology, and recruited scientific co-founders Carolyn Bertozzi, a Stanford professor, and Paul Crocker, a professor and the head of the cell signaling and immunology division at the University of Dundee, Scotland, to help him do it.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.